Opendata, web and dolomites

ONCOGENEVOL SIGNED

The evolutionary history of oncogenic and non-oncogenic papillomaviruses

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOGENEVOL project word cloud

Explore the words cloud of the ONCOGENEVOL project. It provides you a very rough idea of what is the project "ONCOGENEVOL" about.

ancestral    history    genome    occurred    phenotype    carcinogenesis    exception    function    silico    evade    ancestor    paving    cancer    arose    acquired    encode    dna    despite    generate    pv    e7    share    medicine    relationships    virtually    fragmentary    few    human    appearance    acquiring    roots    efforts    humans    back    wet    clinical    explore    functions    evolutionary    public    lesions    directed    regarding    domains    emergence    evolution    benign    hosts    e6    immune    modern    suppressor    oncogene    resurrect    responsible    proteins    fraction    oropharynx    enigma    asymptomatic    pvs    e5    experimentally    certain    vagina    tumor    actually    species    oncogenic    understand    viruses    lab    wart    cancers    anal    infections    vulva    oncogenes    genes    host    allowed    resurrected    papillomaviruses    proto    integration    combining    health    cervical    contexts    manifestations    thereafter    hypotheses    tracking    origin    environmental    ultimate    became    alphapv    small    events    sharing    penis    infection    unfortunate    deep    scenario   

Project "ONCOGENEVOL" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://virostyle.cnrs.fr/projects/oncogenevol/
 Total cost 185˙076 €
 EC max contribution 185˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 185˙076.00

Map

 Project objective

Certain papillomaviruses (PVs) are a major public health concern as in humans they are responsible for virtually all cases of cervical and anal cancer, and for a fraction of cancers on the penis, vagina, vulva and oropharynx. But oncogenic PVs are actually an unfortunate exception, as most PVs cause asymptomatic infections, and a few cause benign, wart-like lesions. Despite the efforts directed towards the understanding of the different clinical manifestations of infection, our knowledge on PV evolution remains fragmentary. Oncogenic human PVs arose recently, after acquiring the E5, E6 and E7 genes. The integration of the E5 proto-oncogene in the ancestral AlphaPV genome allowed viruses to evade host immune response. Thereafter E6 and E7 acquired the ability to target essential tumor suppressor proteins, paving the way for carcinogenesis. Tracking the evolutionary history of the E5, E6 and E7 oncogenes will thus help understand the emergence of oncogenic human PVs. Regarding the deep roots of PVs, small DNA viruses may share a common ancestor as they encode proteins sharing similar functions and domains, but their evolutionary origin is still an enigma. Here I propose to apply an evolutionary medicine approach, combining in silico and wet-lab approaches, to study key events that occurred during PV genome evolution. We will go back into history and study how and when certain PVs became oncogenic. We will resurrect the ancestral oncogenes, and experimentally test hypotheses about the function of the resurrected proteins in different environmental contexts. We will then generate a comprehensive scenario modelling the appearance of the modern PV genome and the emergence of the oncogenic phenotype of certain PVs. Finally we will explore the relationships between small DNA viruses and test whether they may have a common origin. Our ultimate aim is to understand why a few PVs are oncogenic for a few host species, while most PVs cause asymptomatic infections in most hosts.

 Publications

year authors and title journal last update
List of publications.
2019 Anouk Willemsen, Marta Félez-Sánchez, Ignacio G Bravo
Genome Plasticity in Papillomaviruses and De Novo Emergence of E5 Oncogenes
published pages: 1602-1617, ISSN: 1759-6653, DOI: 10.1093/gbe/evz095
Genome Biology and Evolution 11/6 2019-09-02
2019 Anouk Willemsen, Ignacio G. Bravo
Origin and evolution of papillomavirus (onco)genes and genomes
published pages: 20180303, ISSN: 0962-8436, DOI: 10.1098/rstb.2018.0303
Philosophical Transactions of the Royal Society B: Biological Sciences 374/1773 2019-06-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOGENEVOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOGENEVOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

ASIQS (2019)

Antiferromagnetic spintronics investigated by quantum sensing techniques

Read More  

ROSETTA (2020)

Deciphering the Role of aberrant glycOSylation in the rEsponse to Targeted TherApies for breast cancer

Read More